How to integrate monoclonal antibodies targeting the calcitonin gene-related peptide or its receptor in daily clinical practice
Open Access
- 6 May 2019
- journal article
- review article
- Published by Springer Nature in The Journal of Headache and Pain
- Vol. 20 (1) , 1-13
Abstract
Migraine is a major public health issue associated with significant morbidity, considerable negative impact on quality of life, and significant socioeconomic burden. Preventive treatments are required to reduce the occurrence and the severity of acute attacks and to minimize the use of abortive medications and the associate risk of drug-related adverse events, as well as the onset of medication-overuse headache and chronification of migraine. We performed a review of all available evidence on the safety and efficacy of monoclonal antibodies targeting the calcitonin gene-related peptide or its receptor for the preventive treatment of migraine to provide evidence-based guidance on their use in clinical practice. Monoclonal antibodies targeting the calcitonin gene-related peptide or its receptor are mechanism-specific drugs for the preventive treatment of migraine. Double-blind randomized clinical trials have shown that monoclonal antibodies targeting the calcitonin gene-related peptide or its receptor are effective across all the spectrum of migraine patients who require prevention and have a good safety and tolerability profile. Nevertheless, high costs limit the affordability of those drugs at the moment. Specificity, long half-life, efficacy, tolerability, and ease of use make monoclonal antibodies targeting the calcitonin gene-related peptide or its receptor an appealing treatment option for migraine prevention. Optimal strategies to manage treatment over time still need to be clarified with real-life data.Keywords
This publication has 80 references indexed in Scilit:
- Peripheral vascular dysfunction in migraine: a reviewThe Journal of Headache and Pain, 2013
- Origin of pain in migraine: evidence for peripheral sensitisationThe Lancet Neurology, 2009
- Chronic migraine in the populationNeurology, 2008
- Comorbid neuropathologies in migraine: an update on cerebrovascular and cardiovascular aspectsThe Journal of Headache and Pain, 2008
- Clinical Utility of an Instrument Assessing Migraine Disability: The Migraine Disability Assessment (MIDAS) QuestionnaireHeadache: The Journal of Head and Face Pain, 2001
- The trigeminovascular system and migraine: Studies characterizing cerebrovascular and neuropeptide changes seen in humans and catsAnnals of Neurology, 1993
- Vasoactive peptide release in the extracerebral circulation of humans during migraine headacheAnnals of Neurology, 1990
- Calcitonin gene-related peptide-LI in subarachnoid haemorrhage in man. Signs of activation of the trigemino-cerebrovascular system?British Journal Of Neurosurgery, 1990
- Production of a novel neuropeptide encoded by the calcitonin gene via tissue-specific RNA processingNature, 1983
- Alternative RNA processing in calcitonin gene expression generates mRNAs encoding different polypeptide productsNature, 1982